
Soligenix Highlighted in Zacks Report as Key Clinical Milestones Approach Through 2026
Soligenix Inc. is entering a pivotal period with anticipated clinical readouts for its HyBryte and SGX945 programs, which could significantly impact treatment options for rare diseases like CTCL and Behçet's disease.
Read full story




















